Jonathan Levin to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Jonathan Levin has written about Antiretroviral Therapy, Highly Active.
Connection Strength
0,577
-
COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther. 2017; 14:26.
Score: 0,115
-
Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens. J Int Assoc Provid AIDS Care. 2015 Sep-Oct; 14(5):455-62.
Score: 0,097
-
Home-based versus clinic-based care for patients starting antiretroviral therapy with low CD4? cell counts: findings from a cluster-randomized trial. AIDS. 2014 Feb 20; 28(4):569-76.
Score: 0,092
-
Decreasing trends of bacteraemia among HIV-infected Ugandan adults: incidence, aetiology, clinical outcomes and effect of antiretroviral therapy in a semi-urban setting (2000-2008). Trop Med Int Health. 2011 Jun; 16(6):756-65.
Score: 0,075
-
Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):496-9.
Score: 0,071
-
Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res. 2008 Nov 20; 8:241.
Score: 0,064
-
Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study. Malar J. 2016 07 15; 15:361.
Score: 0,027
-
Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment. Trop Med Int Health. 2010 Nov; 15(11):1347-56.
Score: 0,018
-
Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2008 Aug 01; 48(4):468-75.
Score: 0,016